Cargando…

Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti–PD-L1 immunotherapy

Anti–programmed cell death 1 ligand 1 (PD-L1) therapy is extraordinarily effective in select patients with cancer. However, insufficient lymphocytic infiltration, weak T cell–induced inflammation, and immunosuppressive cell accumulation in the tumor microenvironment (TME) may greatly diminish the ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhaoting, Wang, Yixin, Shen, Yuexin, Qian, Chenggen, Oupicky, David, Sun, Minjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228744/ https://www.ncbi.nlm.nih.gov/pubmed/32440550 http://dx.doi.org/10.1126/sciadv.aaz9240

Ejemplares similares

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
por: D’Alterio, Crescenzo, et al.
Publicado: (2019)

Active recruitment of anti–PD-1–conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy
por: Wang, Yixin, et al.
Publicado: (2023)

ATP-activated decrosslinking and charge-reversal vectors for siRNA delivery and cancer therapy
por: Zhou, Zhanwei, et al.
Publicado: (2018)

CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation
por: Ullah, Aftab, et al.
Publicado: (2019)

Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy
por: Zhu, Guizhi, et al.
Publicado: (2017)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy
por: Garbow, Joel R., et al.
Publicado: (2021)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy
por: Han, Zhi-Jian, et al.
Publicado: (2021)

CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy
por: Mezzapelle, Rosanna, et al.
Publicado: (2022)

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
por: Horn, Lucas A, et al.
Publicado: (2020)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
por: Yan, Huiyu, et al.
Publicado: (2023)

GSH depletion liposome adjuvant for augmenting the photothermal immunotherapy of breast cancer
por: Zhou, Zhanwei, et al.
Publicado: (2020)

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
por: Qian, Jiawen, et al.
Publicado: (2018)

Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model
por: Philippou, Yiannis, et al.
Publicado: (2020)

Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy
por: Bullock, Kennady, et al.
Publicado: (2021)

A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention
por: Chen, Jie, et al.
Publicado: (2019)

Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2019)

Self-Assembly Catalase Nanocomplex Conveyed by Bacterial Vesicles for Oxygenated Photodynamic Therapy and Tumor Immunotherapy
por: Zhang, Jiayu, et al.
Publicado: (2022)

Cancer Immunotherapy based on Image-guided STING Activation by Nucleotide Nanocomplex-Decorated Ultrasound Microbubbles
por: Li, Xuefeng, et al.
Publicado: (2022)

The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
por: Hou, Bo, et al.
Publicado: (2023)

Role of CXCR3 signaling in response to anti-PD-1 therapy
por: Han, Xiao, et al.
Publicado: (2019)

PD-L1 degradation pathway and immunotherapy for cancer
por: Gou, Qian, et al.
Publicado: (2020)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
por: Jin, Runsen, et al.
Publicado: (2020)

BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity
por: Cai, Zhiyong, et al.
Publicado: (2023)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
por: Cui, Xin, et al.
Publicado: (2020)

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
por: Zhang, Hao, et al.
Publicado: (2023)

Multifunctional Tannic Acid-Alendronate Nanocomplexes with Antioxidant, Anti-Inflammatory, and Osteogenic Potency
por: Choi, Somang, et al.
Publicado: (2021)

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy
por: Noman, Muhammad Zaeem, et al.
Publicado: (2020)

Formulation of Glycyrrhizic Acid-based Nanocomplexes for Enhanced Anti-cancer and Anti-inflammatory Effects of Curcumin
por: Song, Jihyeon, et al.
Publicado: (2022)

Scalable Manufacture of Curcumin-Loaded Chitosan Nanocomplex for pH-Responsive Delivery by Coordination-Driven Flash Nanocomplexation
por: Xia, Ziwei, et al.
Publicado: (2022)

Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model
por: Zhang, Huan, et al.
Publicado: (2021)

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
por: Liu, Hao, et al.
Publicado: (2022)

CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients
por: D’Alterio, Crescenzo, et al.
Publicado: (2022)

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis
por: Liu, Nian, et al.
Publicado: (2023)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment
por: Zheng, Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ojp0tn5f1nalupr1scb7d3h0if